GSK

AR$9,860.00

▲+2.39%

wb_incandescent Backtest

Stock

GlaxoSmithKline plc

Official Company Name: GlaxoSmithKline plc

Stock Symbol: GSK

Stock Market: Buenos Aires Stock Exchange - BCBA

Currency: Argentine peso - ARS

business GlaxoSmithKline plc Company Profile

GSK Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▲+10.15%

file_download

Daily closing prices, with moving averages and volumes - Argentine peso (ARS)
Moving averages:

  • EMA20
  • SMA50
  • SMA200

Company Description

GlaxoSmithKline PLC, better known as GSK, is a pharmaceutical company. GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes, and mental health, and it also has a portfolio of vaccines. Operating in more than 115 countries, GSK is also engaged in the consumer healthcare business in oral health, pain relief, respiratory, nutrition/gastro-intestinal, and skin health categories.

business GlaxoSmithKline plc Company Profile

GSK Stock Data

Open AR$9,630.00
High AR$9,860.00
Low AR$9,540.00
Close AR$9,860.00
Volume 293
Previous Close AR$9,630.00
1-Day Change 230.00
1-Year Change 908.50
Average Daily Volume 484
52-Week High AR$14,325.00
52-Week Low AR$8,123.50
warning

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.